Hung Michelle E, Leonard Joshua N
From the Interdisciplinary Biological Sciences Program.
Department of Chemical and Biological Engineering, Chemistry of Life Processes Institute, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois 60208
J Biol Chem. 2015 Mar 27;290(13):8166-72. doi: 10.1074/jbc.M114.621383. Epub 2015 Feb 5.
Exosomes are secreted extracellular vesicles that mediate intercellular transfer of cellular contents and are attractive vehicles for therapeutic delivery of bimolecular cargo such as nucleic acids, proteins, and even drugs. Efficient exosome-mediated delivery in vivo requires targeting vesicles for uptake by specific recipient cells. Although exosomes have been successfully targeted to several cellular receptors by displaying peptides on the surface of the exosomes, identifying effective exosome-targeting peptides for other receptors has proven challenging. Furthermore, the biophysical rules governing targeting peptide success remain poorly understood. To evaluate one factor potentially limiting exosome delivery, we investigated whether peptides displayed on the exosome surface are degraded during exosome biogenesis, for example by endosomal proteases. Indeed, peptides fused to the N terminus of exosome-associated transmembrane protein Lamp2b were cleaved in samples derived from both cells and exosomes. To suppress peptide loss, we engineered targeting peptide-Lamp2b fusion proteins to include a glycosylation motif at various positions. Introduction of this glycosylation motif both protected the peptide from degradation and led to an increase in overall Lamp2b fusion protein expression in both cells and exosomes. Moreover, glycosylation-stabilized peptides enhanced targeted delivery of exosomes to neuroblastoma cells, demonstrating that such glycosylation does not ablate peptide-target interactions. Thus, we have identified a strategy for achieving robust display of targeting peptides on the surface of exosomes, which should facilitate the evaluation and development of new exosome-based therapeutics.
外泌体是分泌的细胞外囊泡,介导细胞内容物的细胞间转移,是用于治疗性递送双分子货物(如核酸、蛋白质甚至药物)的有吸引力的载体。体内高效的外泌体介导递送需要将囊泡靶向特定受体细胞进行摄取。尽管通过在外泌体表面展示肽已成功将外泌体靶向几种细胞受体,但为其他受体鉴定有效的外泌体靶向肽已被证明具有挑战性。此外,控制靶向肽成功的生物物理规则仍知之甚少。为了评估可能限制外泌体递送的一个因素,我们研究了外泌体表面展示的肽在其生物发生过程中是否会被降解,例如被内体蛋白酶降解。事实上,与外泌体相关跨膜蛋白Lamp2b的N末端融合的肽在来自细胞和外泌体的样品中均被切割。为了抑制肽的丢失,我们设计了靶向肽-Lamp2b融合蛋白,使其在不同位置包含一个糖基化基序。引入这个糖基化基序既能保护肽不被降解,又能导致细胞和外泌体中Lamp2b融合蛋白的整体表达增加。此外,糖基化稳定的肽增强了外泌体向神经母细胞瘤细胞的靶向递送,表明这种糖基化不会消除肽-靶点相互作用。因此,我们已经确定了一种在外泌体表面实现靶向肽稳定展示的策略,这将有助于评估和开发新的基于外泌体的疗法。